Evidence map›Paper›PMID 41316413›Full record

ArticleTrials2025

Protocol for a randomized controlled trial for comparison of self- and balloon-expandable valves in patients with Ascending Aortic Dilation Undergoing Transcatheter Aortic Valve Replacement (AAD-CHOICE).

Kang An, Fengwen Zhang, Wenbin Ouyang, Shiguo Li, Xiangbin Pan

Registry-linked trialAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in Trials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06009588 (Comparison of Self- and Balloon-expandable Valves in Patients With Ascending Aortic Dilation Undergoing Transcatheter Aortic Valve Replacement), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06009588 narecruitingnot on this map

Comparison of Self- and Balloon-expandable Valves in Patients With Ascending Aortic Dilation Undergoing Transcatheter Aortic Valve Replacement: The AAD-CHOICE

TypeinterventionalSponsorChina National Center for Cardiovascular DiseasesRan2023 to 2026Enrolled100ConditionsAortic Stenosis, Ascending Aortic DilatationArmsself-expandable valves, balloon-expandable valves
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Kang AnDepartment of Structural Heart Disease, National Center for Cardiovascular Disease, China & Fuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No. 167 North Lishi Rd, Xicheng District, Beijing, People's Republic of China.
Fengwen ZhangDepartment of Structural Heart Disease, National Center for Cardiovascular Disease, China & Fuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No. 167 North Lishi Rd, Xicheng District, Beijing, People's Republic of China.
Wenbin OuyangDepartment of Structural Heart Disease, National Center for Cardiovascular Disease, China & Fuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No. 167 North Lishi Rd, Xicheng District, Beijing, People's Republic of China.
Shiguo LiDepartment of Structural Heart Disease, National Center for Cardiovascular Disease, China & Fuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No. 167 North Lishi Rd, Xicheng District, Beijing, People's Republic of China.
Xiangbin PanDepartment of Structural Heart Disease, National Center for Cardiovascular Disease, China & Fuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No. 167 North Lishi Rd, Xicheng District, Beijing, People's Republic of China. panxiangbin@fuwaihospital.org.

Funding

National High Level Talents Special Support Plan 2020-RSW02Noncommunicable Chronic Diseases-National Science and Technology Major Project 2023ZD0514300
6 · The paper itself

Abstract

backgroundSelf-expandable valves (SEVs) and balloon-expandable valves (BEVs) are the most widely used transcatheter heart valves. In patients with ascending aortic dilation (AAD) who undergo transcatheter aortic valve replacement (TAVR), comparison of two type of valves is lacking.

methodsThe AAD-CHOICE trial is a multi-center, randomized controlled, open-label study. The trial will randomly assign 100 patients with AAD (ascending aortic diameter ≥ 45 mm) who undergo TAVR in 1:1 ratio to either SEV group or BEV group. Participants will be followed for a minimum of 1 year. The primary end point is device success, 30-day all-cause mortality and 30-day adverse aortic events. The key secondary end point is 1-year all-cause mortality, 1-year cardiovascular mortality, adverse aortic events, major adverse cardiovascular and cerebrovascular events, and aortic expansion rate ≥ 3 mm/year. DISCUSSION: The study will provide evidence regarding the performance of SEVs and BEVs in patients with AAD who undergo TAVR.

trial registrationClinicalTrials.gov NCT06009588. Registered on August 12, 2023.

Indexed as

AortaAortic ValveAortic Valve StenosisBalloon ValvuloplastyHeart Valve ProsthesisTranscatheter Aortic Valve ReplacementDilatation, PathologicFemaleHumansMaleMulticenter Studies as TopicProsthesis DesignRandomized Controlled Trials as TopicTime FactorsTreatment OutcomeAscending aortic dilationBalloon-expandable valveSelf-expandable valveTranscatheter aortic valve replacement

Identifiers

PMID41316413
PMCPMC12764033

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.